Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis

The increasing prevalence of resistance to currently available antimicrobial agents for bacterial infections, especially for complicated infections caused by Gram-negative bacteria (GNB), is still a challenge [1]. Currently, carbapenems are the first-line recommended therapy for patients with severe infections [2]. However, there is concern that the extensive utilisation of carbapenems may result in an increasing incidence of resistant strains, in particular carbapenem-resistant Enterobacteriaceae (CRE) [3,4].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Review Source Type: research